Aims: The aim of this study was to evaluate treatment of coronary in-stent restenosis (ISR). Conclusions: ISR in BMS should be treated with DES or DEB while the optimal treatment of ISR in DES remains to be proven.
Introduction
Coronary in-stent restenosis (ISR) is a common clinical problem that continues to be one of the most important limitations of percutaneous coronary intervention (PCI). ISR is associated with significant morbidity and costs, and is not a benign entity, with a wide spectrum of clinical presentation 1, 2 . The reported in-stent restenosis frequency varies among different types of stents, characteristics of treated lesions and patient characteristics. ISR occurs in about 15%-35% of lesions treated with a bare metal stent (BMS) 3 , the rate of ISR is usually lower after the implantation of a drug-eluting stent (DES), often less than 10% 4, 5 , but considerably higher when treating more complex lesions 6, 7 . There are no clearly established standards of treatment for ISR, but there are numerous options: DES has shown a considerable and durable advantage over balloon angioplasty 8 and BMS 4, 5 in the treatment of BMS-ISR. The assessment of drug-eluting balloon (DEB) therapy in patients with BMS-ISR has shown consistent results in favour of this device compared with non-coated balloon angioplasty 9 . At present, it remains unclear which strategy is best in the treatment of DES-ISR. Whereas observational studies showed advantages of novel DES implantation over (cutting) balloon angioplasty and vascular brachytherapy (VBT), a recent observational study reported no differences in target lesion revascularisation (TLR) rates between DES and balloon angioplasty on a two-year followup 10 . DEB therapy showed favourable results in smaller trials compared to balloon angioplasty in the treatment of DES-ISR 11, 12 . Since the use of DES is now widespread even in complex lesions and offlabel indications, the problem of ISR in drug-eluting stents is not negligible. Treatment results are considerably worse compared to BMS-ISR, and rates of re-restenosis are consistently higher 13 .
The Swedish Angiography and Angioplasty Registry (SCAAR) registry, with complete nationwide enrolment and registration of restenosis of any previously implanted stent anywhere in the country, offered a unique opportunity to evaluate treatment for ISR.
Methods

STUDY POPULATION
Our study included all PCI-treated coronary in-stent restenosis (ISR) in Sweden from January 1 st 2005 to March 3 rd 2012. The data were analysed with regard to different types of treatment, patient and stenosis characteristics. The primary objective was to evaluate the results of different types of treatment for ISR as detected in clinically driven angiography. The study endpoint was occurrence of re-restenosis until the end of the follow-up period. Re-restenosis was defined as a luminal renarrowing of at least 50% at follow-up angiography in a previously treated coronary segment.
SCAAR DATA
The SCAAR data have been described elsewhere 14 .
STATISTICAL ANALYSIS
We summarised baseline characteristics of the patients with mean and standard deviations for continuous variables and percentages for discrete variables. Cumulative event rates were estimated by the Kaplan-Meier method. The primary objective was to evaluate incidence and outcome after treatment of coronary in-stent restenosis. The primary outcome variable was clinically driven restenosis with angiographic confirmation. As a secondary event, we also analysed repeat target lesion revascularisation performed with PCI, PCI-TLR. The cumulative adjusted relative risk of the primary outcome variable was calculated using the Cox proportional hazard method with the variables shown in 15 . Due to the limited number of events in the analysis of change of stent drug in DES-ISR, only these variables were forced into the statistical model when change of stent drug was analysed: change of drug, diameter of the stent, length of the stent, diabetes, treated vessel, year of treatment, treating hospital and indication of the procedure.
In an additional analysis we tested the statistical interaction between change of drug (change/no change) and type of drug (sirolimus/paclitaxel/everolimus/zotarolimus/biolimus) by introducing an interaction term, "change of drug* type of drug" into the statistical model. If diameter or length was unknown the information was taken from the original stent. All reported p-values are two-sided. The analyses were performed with the use of SPSS statistical software version 19.0 (SPSS Inc., Chicago, IL, USA) or Stata/MP version 12.1 (StataCorp LP, College Station, TX, USA).
Results
During the study period 212,166 coronary lesions were treated in Sweden (Figure 1) , of which 11,442 were recorded in the registry as in-stent restenosis and of these the type and the characteristics of the original stent were known in 8,209 cases. The study population consisted of 7,806 ISR after removal of 403 ISR with a more unusual new treatment or just wire attempt. DES was the most common new treatment in ISR, with 4,335 stents, while BMS was used in 647, DEB in 664 (in 27 cases with additional BMS) and balloon angioplasty in 2,160 ISR. The DEBs used were SeQuent ® Please (B. Braun AG, Melsungen, Germany) in 82% of the cases, Elutax (Aachen Resonance GmbH, Aachen, Germany) in 14%, and two other types of DEBs in less than 5%. The original stent was a BMS in 5,177 cases and a DES in 2,629 cases. The background and procedural factors in these two groups are summarised in Table 1 . Treatment of ISR with DES, BMS and balloon angioplasty had similar follow-up durations (1,266±707 days, 1,204±755 days and 1,245±724 days, respectively). DEB treatment of ISR had a considerably shorter follow-up time (430±271 days). In total, 1,079 re-restenoses occurred, 592 in BMS-ISR and 487 in DES-ISR. As depicted in Figure 1 , ISR in BMS were mainly treated with a DES (62%), by balloon angioplasty (21%), new BMS (9.5%), and DEB (7.2%). ISR in DES were treated with a new DES, balloon dilatation, DEB and BMS in 43%, 40%, 11% and 6%, respectively. The long-term incidence of new restenosis (re-restenosis) of these ISR is illustrated in Figure 2 . The rates of new restenosis were generally low. For the new treatment with DES, DEB, BMS and balloon angioplasty the recorded rates of re-restenosis within a year were 7%, 8%, 13% and 13%, respectively. When the original stent was a DES the risk of a re-restenosis after the new invasive treatment was higher compared to treatment of BMS-ISR, HR (95% CI) 1.80 (1.59-2.03), p<0.001, Figure 3 .
The effects of different ISR treatments are shown in Table 2 . Table 3 shows the results when analysing treatment results of only one ISR per patient. With DES treatment of ISR, independent of initial stent type, the unadjusted and adjusted risk of new restenosis was lower as 161  162  163  164  165  166  167  168  169  170  171  172  173  174  175  176  177  178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212 compared with treatment with BMS and with balloon angioplasty. Treatment with DEB had a lower risk of a re-restenosis than BMS, but not statistically different as compared with balloon angioplasty. There was also a trend towards a lower risk of re-restenosis for balloon angioplasty compared to BMS. In the statistical model, a significant interaction was found between the type of original stent (DES/BMS) and the type of ISR treatment, p=0.032. The crude incidence of re-restenosis dependent on the original stent type is shown in Figure 3 , and the cumulative adjusted risk of re-restenosis for the two types of original stent (DES and BMS) and for the four major different ISR treatments separately in Figure 4A and Figure 4B . Treatment results of BMS-ISR differ largely in contrast to DES-ISR. When comparing "old DES" (n=2,921) vs. "new DES" (n=1,422) no significant statistical difference was found, HR (95% CI) 0.85 (0.66-1.10), p=0.213.
BMS-ISR
In BMS-ISR new treatment with a DES was associated with a significantly lower risk of re-restenosis, compared to both balloon angioplasty and BMS. The risk was more than halved when a DES was used compared to a BMS. For balloon angioplasty the risk of a subsequent new restenosis was lower compared to novel BMS implantation. For DEB the adjusted incidence was significantly lower as compared to a new BMS and in the unadjusted model as compared to balloon angioplasty. However, after adjustment this statistically significant difference disappeared.
DES-ISR
In the treatment of DES-ISR the only statistically significant difference was a lower risk of re-restenosis with novel DES implantation compared to balloon angioplasty. There were no differences in re-restenosis rates among the use of DES, BMS and DEB compared to each other in DES-ISR. In 1,122 cases the DES-ISR was treated with a new DES. In these pairs of DES, 61% had the same drug on both stents and in 49% of pairs the drug on the new stent was different from the first one. 215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231  232  233  234  235  236  237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265 cohort of unselected, consecutive patients from all interventional centres in Sweden. Patients with ISR presented in 67% with acute coronary syndrome (ACS), while 18.3% presented with ST-segment elevation myocardial infarction, emphasising again the severity of the disease.
In the study period we encountered a variety of different interventional therapies with different outcome. In general, there was a good effect of PCI treatment of restenosis: in about 85-90% of the lesions there was no reporting of a new restenosis during the first year. However, we found a considerable difference in the risk of 
Discussion
In this study, we evaluated the long-term outcome after treatment of ISR with different types of interventional therapy in a very large 267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317 318 re-restenosis between the two types of the original stents. When the original stent was a DES, the risk of re-restenosis was 1.8 times higher than if the original stent was a BMS. Thus, when a restenosis occurs in a DES (which is a rarer event compared to restenosis in BMS), there is a higher risk for re-restenosis 13 .
BMS-ISR
Drug-eluting devices showed good results in BMS-ISR ( Figure  4A ) with a reduction of the risk of a new restenosis for both DES and for DEB compared to novel BMS implantation. Also, compared to balloon angioplasty, drug-eluting devices had a better effect, significantly so for DES versus balloon angioplasty but only as a trend when DEB was compared to balloon angioplasty. The only randomised controlled trial comparing novel BMS implantation to balloon angioplasty in the treatment of BMS-ISR showed that the binary restenosis rate and the one-year event-free survival rate were similar in both groups 16 . In our study balloon angioplasty had a better effect than using a new BMS in BMS-ISR. Similarly, in an earlier observational study 17 , BMS did not reduce TLR or death at one year compared to balloon angioplasty in the treatment of BMS-ISR. Our study shows the lower clinical need for reintervention after use of drug-eluting devices for the treatment of BMS-ISR, as has been described previously 14, 18, 19 . In a recent retrospective trial for the treatment of BMS-ISR 18 , DES were associated with a significantly lower composite endpoint of all-cause mortality, MI or TLR when compared to BMS at 3.2 years of follow-up (21% versus 45%, p=0.03).
The DEB technique represents a new treatment alternative. First data in randomised controlled trials showed favourable results in the treatment of BMS-ISR compared to balloon angioplasty 20 and paclitaxel-eluting stents 21 .
DES-ISR
While DES use is an effective treatment for patients with BMS restenosis, the same cannot be said for patients with DES restenosis. In our study the adjusted risk of new restenosis in a DES-ISR is higher compared to the risk of new restenosis after treatment of a BMS-ISR. Many observational studies have evaluated outcomes after PCI for DES-ISR, but numbers of enrolled patients have been too small and results too inconsistent to draw definitive conclusions about the optimal treatment of DES-ISR
23
. Data of the Japanese j-Cypher registry, evaluating 1,094 sirolimus-eluting stent (SES) ISR, comparing re-SES therapy versus balloon angioplasty, showed significantly lower TLR rates in the re-SES cohort (23.8% vs. 37.7%, p<0.0001), without differences in two-year mortality 24 . Smaller randomised trials 11, 12 showed superiority of the DEB compared to plain balloon dilatation in patients with DES-ISR on 131 11 versus 50 12 patients.
This fact could not be confirmed in our study including 290 DEBtreated DES-ISR. Compared to balloon angioplasty none of the three major treatment options (re-DES, BMS or DEB) showed superiority. Only after adjustment, using multivariate regression Cumulative incidence of re-restenosis (%) analysis, did the implantation of a second DES become statistically significantly better than balloon angioplasty in the treatment of DES-ISR. Compared to BMS implantation in a DES-ISR, neither re-DES nor DEB therapy showed superiority. Our analysis showed that the implantation of a second DES carrying a drug different from the one that was used before does not show any advantage compared to the application of a DES with the same drug again (Figure 5 ), which is in accordance with most 25, 26 but not all 27 data in the literature. In our registry analysis, treatment groups were heterogenous. In the DES group different types of first and second-generation stents were used, and in the DEB group four different types of drug-coated balloons were evaluated. According to a recent investigation 28 , efficacy varies largely among the different devices. In our study, 14% of the DEBs used belonged to the type of DEB with the lowest efficacy, which may have had a negative impact on the restenosis rate.
The inherent limitations of a non-randomised registry study should be acknowledged. The findings should be regarded as hypothesis-generating. Despite appropriate statistical adjustments, unknown confounders may have affected the results. Moreover, it is not possible to attribute individual events to the individual stents or the stented vessel. Some patients presenting with ISR could not be followed up because the previously treated segment was renamed on a later occasion. Patients with clinically relevant ISR who underwent bypass surgery or were treated medically were also not studied.
The pattern of restenosis (focal/non-focal) has an important impact on the treatment result, but these data are currently not available in the SCAAR database. The choice of stent type was based on the operator's decision, which could possibly have introduced selection bias. Since we did not differentiate the pattern of restenosis, acute stent thrombosis may also have been falsely coded as restenosis by the operator in a few cases, possibly explaining the relatively high number of patients with STEMI. However, there is also evidence that a severe restenosis may present with acute stent occlusion and ST elevation. 
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